Lotus Eye Hospital Q1 FY27 profit rises 13% on 26% revenue growth

Revenue Growth 20pctEbitda Margin ExpansionExceptional ItemResults View source PDF Explain this filing

LOTUSEYE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+3.5%Reaction day

₹115.60

prior close

₹116.95

announcement price

After-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.2%+3.6% vs market

Hospital peers, median of 25sector-1.3%+4.7% vs sector

On the reaction day the stock moved 3.6 pts more than Nifty Microcap 250 and 4.7 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.8

10m

+3.4

15m

+2.6

30m

+2.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+3.5-0.2+3.6-1.3+4.7

Next day

+1.7+0.2+1.5-2.2+3.9

+1.1+0.4+0.8-3.0+4.1

-0.5+0.4-0.9-2.0+1.5

+0.3+0.6-0.2-2.9+3.3

+0.8+0.9-0.2-2.1+2.9

+2.0+0.9+1.2-3.8+5.8

15d

-6.1+0.9-7.1-3.6-2.6

-1.8+2.3-4.2-3.0+1.2

-6.2-1.1-5.1-12.8+6.6

—————

UpDownMarket · Nifty Microcap 250Sector · Hospital peers, median of 25Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Board approved standalone unaudited results for quarter ended June 30, 2026. Revenue from operations grew 26% YoY to about Rs 17.06 crore from Rs 13.52 crore. Net profit rose to Rs 61.37 lakh versus Rs 54.48 lakh, up 13%. EBITDA margin expanded to about 18% from 11% YoY, aided by lower finance costs and operating leverage. Statutory auditors issued an unqualified limited review report.

Likely market impact

Strong revenue growth and margin expansion suggest improving operations; likely to be viewed positively by investors.